Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Shares Outstanding (Weighted Average) (2021 - 2025)

Historic Shares Outstanding (Weighted Average) for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $62.0 million.

  • Janux Therapeutics' Shares Outstanding (Weighted Average) rose 1353.69% to $62.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.0 million, marking a year-over-year increase of 1353.69%. This contributed to the annual value of $53.8 million for FY2024, which is 2211.73% up from last year.
  • According to the latest figures from Q3 2025, Janux Therapeutics' Shares Outstanding (Weighted Average) is $62.0 million, which was up 1353.69% from $61.9 million recorded in Q2 2025.
  • Janux Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $62.0 million for Q3 2025, and its period low was $1.1 million during Q1 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $41.8 million (2023), whereas its average is $42.8 million.
  • In the last 5 years, Janux Therapeutics' Shares Outstanding (Weighted Average) surged by 425911.61% in 2021 and then soared by 93.49% in 2023.
  • Janux Therapeutics' Shares Outstanding (Weighted Average) (Quarter) stood at $23.5 million in 2021, then soared by 76.24% to $41.5 million in 2022, then grew by 6.14% to $44.0 million in 2023, then increased by 22.12% to $53.8 million in 2024, then grew by 15.39% to $62.0 million in 2025.
  • Its last three reported values are $62.0 million in Q3 2025, $61.9 million for Q2 2025, and $61.8 million during Q1 2025.